From pharmacogenetics and ecogenetics to pharmacogenomics

Area of Science:

• Pharmacogenetics and Pharmacogenomics
• Ecogenetics and Nutrigenomics

Background:

• The historical development of pharmacogenetics traces back to early observations by Garrod, Haldane, and R.J. Williams.
• Key milestones include Motulsky's delineation in 1957, Vogel's coining of 'pharmacogenetics' in 1959, and Kalow's 1962 monograph establishing the discipline.
• Twin studies in the 1970s confirmed the significance of polygenic inheritance in drug metabolism.

Observation:

• Ecogenetics, defined by Brewer in 1971, studies genetic variations in response to environmental agents, particularly xenobiotics.
• The advent of novel genomic techniques in the 1990s led to the term pharmacogenomics, broadening the field's scope.
• Genetic and genomic approaches are now integrated into initiatives like the 'Environmental Genome Project', encompassing toxicogenetics and toxicogenomics.

Findings:

• Nutritional ecogenetics (Nutrigenomics) investigates the interplay between genetic variations, dietary factors, nutritional needs, and susceptibility to chronic diseases.
• Pharmacogenomics utilizes genetic and genomic data to understand individual drug responses.
• While the promise of pharmacogenomics is significant, its impact is more likely to be seen in personalized drug selection and minimizing adverse drug reactions rather than a complete therapeutic revolution.

Implications:

• Pharmacogenomic approaches offer potential for optimizing drug therapy and preventing adverse events.
• The field's development highlights the increasing integration of genetic and environmental factors in understanding health and disease.
• Caution is advised regarding premature commercialization, emphasizing a balanced perspective on the current and future impact of pharmacogenomics.